Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Extended lab space for product development, customer demos, and training
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Encourages working women to practice self-care
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Subscribe To Our Newsletter & Stay Updated
